Capecitabine Pill

Phase 2Small molecule

PPeter MacCallum Cancer Centre, Australia

Capecitabine Pill is one of 45 small molecule programs targeting Metastatic Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Breast CancerRecruiting

Metastatic Breast CancerPhase 2

Recruiting

Competition

Competitive Landscape

46 competitors in Metastatic Breast Cancer

#DrugCompanyPhaseTrials

Kisqali

Novartis

Approved

6 2

Femara

Novartis

Approved

3 3

Nolvadex

AstraZeneca

Approved

2 4

Faslodex

FFresenius Kabi USA, LLC

Approved

8 5

Arimidex

IIstituto Clinico Humanitas

Approved

3 6

Zoladex

TTerSera Therapeutics LLC

Approved

1 7

Herceptin

Roche

Phase 3

5 8

Taxol

Teva

Phase 3

3 9

Abraxane

Bristol-Myers Squibb

Phase 3

3 10

Aromasin

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Metastatic Breast Cancer

NCT06105684

Clinical

Trials by Indication[1]

Locally-advanced Rectal Cancer1 trial

Avelumab With Chemoradiation in Locally Advanced Rectal Cancer

Completed·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT03299660·37 enrolled

Metastatic Breast Cancer1 trial

Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer

Recruiting·UUniversity of Alabama at Birmingham·Phase 2·NCT06105684·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Capecitabine Pill. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Capecitabine Pill compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Capecitabine Pill. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peter MacCallum Cancer Centre, Australia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPeter MacCallum Cancer Centre, Australia

Capecitabine Pill

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Locally-advanced Rectal Cancer1 trial

Metastatic Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News